385 related articles for article (PubMed ID: 29141633)
21. A simultaneous knockout knockin genome editing strategy in HSPCs potently inhibits CCR5- and CXCR4-tropic HIV-1 infection.
Dudek AM; Feist WN; Sasu EJ; Luna SE; Ben-Efraim K; Bak RO; Cepika AM; Porteus MH
Cell Stem Cell; 2024 Apr; 31(4):499-518.e6. PubMed ID: 38579682
[TBL] [Abstract][Full Text] [Related]
22. Genome editing of the HIV co-receptors CCR5 and CXCR4 by CRISPR-Cas9 protects CD4
Liu Z; Chen S; Jin X; Wang Q; Yang K; Li C; Xiao Q; Hou P; Liu S; Wu S; Hou W; Xiong Y; Kong C; Zhao X; Wu L; Li C; Sun G; Guo D
Cell Biosci; 2017; 7():47. PubMed ID: 28904745
[TBL] [Abstract][Full Text] [Related]
23. Glycosylphosphatidylinositol-Anchored Anti-HIV scFv Efficiently Protects CD4 T Cells from HIV-1 Infection and Deletion in hu-PBL Mice.
Ye C; Wang W; Cheng L; Li G; Wen M; Wang Q; Zhang Q; Li D; Zhou P; Su L
J Virol; 2017 Feb; 91(3):. PubMed ID: 27881659
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of hepatitis B virus replication via HBV DNA cleavage by Cas9 from Staphylococcus aureus.
Liu Y; Zhao M; Gong M; Xu Y; Xie C; Deng H; Li X; Wu H; Wang Z
Antiviral Res; 2018 Apr; 152():58-67. PubMed ID: 29458131
[TBL] [Abstract][Full Text] [Related]
25. Efficient Editing of the CXCR4 Locus Using Cas9 Ribonucleoprotein Complexes Stabilized with Polyglutamic Acid.
Golubev DS; Komkov DS; Shepelev MV; Mazurov DV; Kruglova NA
Dokl Biol Sci; 2023 Dec; 513(Suppl 1):S28-S32. PubMed ID: 38190037
[TBL] [Abstract][Full Text] [Related]
26. Using
Zhang Y; Cai Y; Sun S; Han T; Chen L; Hou W
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361580
[TBL] [Abstract][Full Text] [Related]
27. CRISPR-Cas9 genome engineering of primary CD4
Hultquist JF; Hiatt J; Schumann K; McGregor MJ; Roth TL; Haas P; Doudna JA; Marson A; Krogan NJ
Nat Protoc; 2019 Jan; 14(1):1-27. PubMed ID: 30559373
[TBL] [Abstract][Full Text] [Related]
28. Excision of HIV-1 DNA by gene editing: a proof-of-concept in vivo study.
Kaminski R; Bella R; Yin C; Otte J; Ferrante P; Gendelman HE; Li H; Booze R; Gordon J; Hu W; Khalili K
Gene Ther; 2016 Aug; 23(8-9):690-5. PubMed ID: 27194423
[TBL] [Abstract][Full Text] [Related]
29. Two high-fidelity variants: efSaCas9 and SaCas9-HF, which one is better?
Lv J; Xi H; Lv X; Zhou Y; Wang J; Chen H; Yan T; Jin J; Zhao J; Gu F; Song Z
Gene Ther; 2022 Aug; 29(7-8):458-463. PubMed ID: 35095097
[TBL] [Abstract][Full Text] [Related]
30. Design of SaCas9-HF for In Vivo Gene Therapy.
Tiwari K; Kumar R; Saudagar P
Methods Mol Biol; 2023; 2575():261-268. PubMed ID: 36301479
[TBL] [Abstract][Full Text] [Related]
31. Highly specific targeted mutagenesis in plants using Staphylococcus aureus Cas9.
Kaya H; Mikami M; Endo A; Endo M; Toki S
Sci Rep; 2016 May; 6():26871. PubMed ID: 27226350
[TBL] [Abstract][Full Text] [Related]
32. CRISPR-Edited Stem Cell Transplantation for HIV-Related Gene Modification In Vivo: A Systematic Review.
Widjaya MA; Ju JC; Lee SD
Stem Cell Rev Rep; 2022 Jun; 18(5):1743-1755. PubMed ID: 35169967
[TBL] [Abstract][Full Text] [Related]
33. Expanding the CRISPR imaging toolset with Staphylococcus aureus Cas9 for simultaneous imaging of multiple genomic loci.
Chen B; Hu J; Almeida R; Liu H; Balakrishnan S; Covill-Cooke C; Lim WA; Huang B
Nucleic Acids Res; 2016 May; 44(8):e75. PubMed ID: 26740581
[TBL] [Abstract][Full Text] [Related]
34. CRISPR/Cas9 genome editing of CCR5 combined with C46 HIV-1 fusion inhibitor for cellular resistant to R5 and X4 tropic HIV-1.
Khamaikawin W; Saisawang C; Tassaneetrithep B; Bhukhai K; Phanthong P; Borwornpinyo S; Phuphuakrat A; Pasomsub E; Chaisavaneeyakorn S; Anurathapan U; Apiwattanakul N; Hongeng S
Sci Rep; 2024 May; 14(1):10852. PubMed ID: 38741006
[TBL] [Abstract][Full Text] [Related]
35. AAV-CRISPR Gene Editing Is Negated by Pre-existing Immunity to Cas9.
Li A; Tanner MR; Lee CM; Hurley AE; De Giorgi M; Jarrett KE; Davis TH; Doerfler AM; Bao G; Beeton C; Lagor WR
Mol Ther; 2020 Jun; 28(6):1432-1441. PubMed ID: 32348718
[TBL] [Abstract][Full Text] [Related]
36. Zinc-finger nuclease editing of human cxcr4 promotes HIV-1 CD4(+) T cell resistance and enrichment.
Yuan J; Wang J; Crain K; Fearns C; Kim KA; Hua KL; Gregory PD; Holmes MC; Torbett BE
Mol Ther; 2012 Apr; 20(4):849-59. PubMed ID: 22273578
[TBL] [Abstract][Full Text] [Related]
37. Rational Selection of CRISPR-Cas Triggering Homology-Directed Repair in Human Cells.
Li F; Zhou C; Tu T; Liu Y; Lv X; Wang B; Song Z; Zhao Q; Liu C; Gu F; Zhao J
Hum Gene Ther; 2021 Mar; 32(5-6):302-309. PubMed ID: 33323021
[TBL] [Abstract][Full Text] [Related]
38. CCL2 increases X4-tropic HIV-1 entry into resting CD4+ T cells.
Campbell GR; Spector SA
J Biol Chem; 2008 Nov; 283(45):30745-53. PubMed ID: 18784079
[TBL] [Abstract][Full Text] [Related]
39. Generation of knock-in primary human T cells using Cas9 ribonucleoproteins.
Schumann K; Lin S; Boyer E; Simeonov DR; Subramaniam M; Gate RE; Haliburton GE; Ye CJ; Bluestone JA; Doudna JA; Marson A
Proc Natl Acad Sci U S A; 2015 Aug; 112(33):10437-42. PubMed ID: 26216948
[TBL] [Abstract][Full Text] [Related]
40. In vivo genome editing using Staphylococcus aureus Cas9.
Ran FA; Cong L; Yan WX; Scott DA; Gootenberg JS; Kriz AJ; Zetsche B; Shalem O; Wu X; Makarova KS; Koonin EV; Sharp PA; Zhang F
Nature; 2015 Apr; 520(7546):186-91. PubMed ID: 25830891
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
